S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
30 Days of MarketBeat All Access Free (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
"This Could be the Biggest Stock Story of 2023" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
30 Days of MarketBeat All Access Free (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
"This Could be the Biggest Stock Story of 2023" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
30 Days of MarketBeat All Access Free (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
"This Could be the Biggest Stock Story of 2023" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
30 Days of MarketBeat All Access Free (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
"This Could be the Biggest Stock Story of 2023" (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:TVTX

Travere Therapeutics (TVTX) Stock Forecast, Price & News

$7.85
+0.21 (+2.75%)
(As of 09/22/2023 ET)
Compare
Today's Range
$7.18
$7.95
50-Day Range
$7.64
$17.25
52-Week Range
$7.00
$26.55
Volume
7.45 million shs
Average Volume
1.86 million shs
Market Capitalization
$588.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.77

Travere Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
190.1% Upside
$22.77 Price Target
Short Interest
Bearish
11.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.27mentions of Travere Therapeutics in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$98,954 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.59) to ($4.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

624th out of 963 stocks

Pharmaceutical Preparations Industry

288th out of 458 stocks


TVTX stock logo

About Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

TVTX Price History

TVTX Stock News Headlines

Unusual Passive Income Investment (Found on a Golf Course)
One man turned $1,000 into a decades long passive income stream... eventually reaching $100,000 per year! All from a single golf course tip. CLICK HERE TO FIND OUT HOW HE DID IT
Travere Therapeutics (NASDAQ:TVTX) PT Lowered to $18.00
Travere Therapeutics (NASDAQ:TVTX) PT Lowered to $12.00
Travere Therapeutics (NASDAQ:TVTX) Price Target Cut to $18.00
Travere Therapeutics (NASDAQ:TVTX) PT Lowered to $14.00
Unusual Passive Income Investment (Found on a Golf Course)
One man turned $1,000 into a decades long passive income stream... eventually reaching $100,000 per year! All from a single golf course tip. CLICK HERE TO FIND OUT HOW HE DID IT
Travere Therapeutics (NASDAQ:TVTX) Downgraded by William Blair
See More Headlines
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TVTX Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TVTX
Employees
462
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.77
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+190.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

Net Income
$-278,480,000.00
Net Margins
-136.00%
Pretax Margin
-135.85%

Debt

Sales & Book Value

Annual Sales
$212.02 million
Book Value
$0.67 per share

Miscellaneous

Free Float
72,198,000
Market Cap
$588.83 million
Optionable
Optionable
Beta
0.42
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Eric M. Dube Ph.D. (Age 50)
    Pres, CEO & Director
    Comp: $1.35M
  • Mr. Christopher Cline C.F.A. (Age 38)
    CFA, Chief Financial Officer
    Comp: $634.36k
  • Dr. William E. Rote Ph.D. (Age 60)
    Sr. VP and Head of R&D
    Comp: $733.25k
  • Mr. Peter HeermaMr. Peter Heerma (Age 52)
    Chief Commercial Officer
    Comp: $705.62k
  • Dr. Jula Inrig M.D. (Age 48)
    Chief Medical Officer
    Comp: $815.93k
  • Ms. Sandra CalvinMs. Sandra Calvin (Age 57)
    SVP, Corp. Controller & Chief Accounting Officer
  • Ms. Elizabeth E. ReedMs. Elizabeth E. Reed (Age 52)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Charlotte Smith
    Sr. VP of Public Affairs
  • Mr. Casey Logan
    Sr. VP of Corp. & Bus. Devel.
  • Ms. Angela Giannantonio
    Sr. VP of HR













TVTX Stock - Frequently Asked Questions

Should I buy or sell Travere Therapeutics stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TVTX shares.
View TVTX analyst ratings
or view top-rated stocks.

What is Travere Therapeutics' stock price forecast for 2023?

15 brokers have issued 1 year price targets for Travere Therapeutics' stock. Their TVTX share price forecasts range from $8.00 to $38.00. On average, they expect the company's share price to reach $22.77 in the next year. This suggests a possible upside of 190.1% from the stock's current price.
View analysts price targets for TVTX
or view top-rated stocks among Wall Street analysts.

How have TVTX shares performed in 2023?

Travere Therapeutics' stock was trading at $21.03 on January 1st, 2023. Since then, TVTX stock has decreased by 62.7% and is now trading at $7.85.
View the best growth stocks for 2023 here
.

When is Travere Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TVTX earnings forecast
.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.03. The company earned $59.70 million during the quarter, compared to analysts' expectations of $53.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 273.80% and a negative net margin of 136.00%.

What ETFs hold Travere Therapeutics' stock?
What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Deep Track Capital LP (9.83%), State Street Corp (7.64%), Renaissance Technologies LLC (2.07%), Kynam Capital Management LP (1.94%), Geode Capital Management LLC (1.86%) and Assenagon Asset Management S.A. (1.47%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends
.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Travere Therapeutics' stock price today?

One share of TVTX stock can currently be purchased for approximately $7.85.

How much money does Travere Therapeutics make?

Travere Therapeutics (NASDAQ:TVTX) has a market capitalization of $588.83 million and generates $212.02 million in revenue each year. The company earns $-278,480,000.00 in net income (profit) each year or ($4.52) on an earnings per share basis.

How many employees does Travere Therapeutics have?

The company employs 462 workers across the globe.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.retrophin.com. The company can be reached via phone at (888) 969-7879, via email at ir@retrophin.com, or via fax at 302-645-1280.

This page (NASDAQ:TVTX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -